ReportWire

Tag: IWM

  • ANB Bank Sells 2,046 Shares of iShares Russell 2000 ETF $IWM

    ANB Bank reduced its position in shares of iShares Russell 2000 ETF (NYSEARCA:IWMFree Report) by 12.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 14,836 shares of the exchange traded fund’s stock after selling 2,046 shares during the period. iShares Russell 2000 ETF accounts for about 1.4% of ANB Bank’s investment portfolio, making the stock its 17th largest holding. ANB Bank’s holdings in iShares Russell 2000 ETF were worth $3,201,000 as of its most recent SEC filing.

    Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quaker Wealth Management LLC increased its holdings in shares of iShares Russell 2000 ETF by 211.1% during the second quarter. Quaker Wealth Management LLC now owns 120 shares of the exchange traded fund’s stock worth $26,000 after buying an additional 228 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in iShares Russell 2000 ETF during the 2nd quarter worth approximately $28,000. Financial Network Wealth Advisors LLC bought a new stake in iShares Russell 2000 ETF during the 1st quarter worth approximately $29,000. Brooklyn Investment Group acquired a new stake in iShares Russell 2000 ETF during the 1st quarter valued at $30,000. Finally, Proathlete Wealth Management LLC bought a new position in iShares Russell 2000 ETF in the 2nd quarter valued at $30,000.

    iShares Russell 2000 ETF Stock Performance

    iShares Russell 2000 ETF stock opened at $237.48 on Friday. The business’s fifty day moving average is $243.28 and its two-hundred day moving average is $226.15. The firm has a market cap of $65.77 billion, a P/E ratio of 17.69 and a beta of 1.13. iShares Russell 2000 ETF has a 52 week low of $171.73 and a 52 week high of $252.77.

    About iShares Russell 2000 ETF

    (Free Report)

    iShares Russell 2000 ETF (the Fund) is an exchange-traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Russell 2000 Index (the Index). The Index is a float-adjusted capitalization weighted index that measures the performance of the small-capitalization sector of the United States equity market and includes securities issued by the approximately 2,000 smallest issuers in the Russell 3000 Index.

    Further Reading

    Want to see what other hedge funds are holding IWM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Russell 2000 ETF (NYSEARCA:IWMFree Report).

    Institutional Ownership by Quarter for iShares Russell 2000 ETF (NYSEARCA:IWM)



    Receive News & Ratings for iShares Russell 2000 ETF Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iShares Russell 2000 ETF and related companies with MarketBeat.com’s FREE daily email newsletter.

    ABMN Staff

    Source link

  • Rounded Bottom Formation Shows When Dogecoin Price Will Begin ‘Flying’

    Despite consolidating around the $0.24 area for months now, a new technical analysis suggests that the Dogecoin price could be gearing up for another explosive move this cycle. A crypto analyst has identified a recurring rounded bottom pattern in DOGE’s historic price chart, suggesting a familiar setup that often precedes massive rallies. The analyst argues that a combination of technical structure and macroeconomic conditions could once again send Dogecoin flying. 

    Macro Correlations Suggest Dogecoin Price Rally Ahead

    In an extensive analysis shared on X social media, crypto market analyst Osemka highlighted a recurring pattern of rounded bottom formations in Dogecoin’s long-term price chart. His study compares the meme coin’s price behaviour against the iShares Russell 2000 ETF (IWM) and other altcoins collectively labelled as “ALTS (OTHERS),” illustrating how macroeconomic cycles influence crypto risk assets. 

    The chart showcases how altcoins and the IWM help depict how the Dogecoin price historically lags behind broader market movements during early “risk-on” phases before entering its explosive bullish phase. Osemka pointed out that once IWM breaks out, altcoins typically begin to rally, yet DOGE remains dormant for a short period. However, the real price acceleration tends to occur only after the altcoin index surpasses its previous all-time high. 

    The cyclical lag effect of the rounded bottom series positions the Dogecoin price as a late mover that benefits from the spillover momentum from IWM and “OTHERS.” The patterns mark long consolidation phases of accumulation before the analyst’s projected parabolic ascent begins. More importantly, the current market appears to align with these same pre-rally conditions, signaling that the meme coin is getting ready to “fly” but only when the macro environment shifts to “risk-on mode.”

    Expert Eyes Upcoming Dogecoin Price Discovery 

    In a separate analysis, ‘Zero,’ another crypto market expert on X reinforced Dogecoin’s bullish thesis by emphasizing that a price discovery is imminent. His long-term chart, dating back to 2014, outlines three major accumulation and expansion cycles, each undergoing its own level of sideways action before a dramatic surge. 

    The chart highlights previous explosive phases of 218x and 548x during past bull markets, with a projected 50x move, suggesting that Dogecoin is once again nearing the end of a consolidation phase and preparing for a major breakout. The green shaded area on Zero’s chart represents historical accumulation zones—the quiet consolidation periods that often precede strong price rallies.

    Dogecoin

    Scott Matherson

    Source link

  • The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks

    The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks

    The Russell 2000 Index soared 12% in December, which might reflect investors’ exuberance about the state of the U.S. economy — it appears the Federal Reserve has won its battle against inflation.

    But if you are looking to broaden your exposure to the stock market beyond the large-cap S&P 500
    SPX,
    buying shares of a fund that tracks the Russell 2000 Index
    RUT
    might not be the best way to do it. This is because the Russell 2000 isn’t selective — it is made up of the smallest 2,000 companies by market capitalization in the Russell 3000 Index
    RUA,
    which itself is designed to capture about 98% of the U.S. public equity market.

    A better choice might be the S&P Small Cap 600 Index
    SML
    because S&P Global requires companies to show four consecutive quarters of profitability to be initially included in the index, among other criteria.

    Below is a screen of analysts’ favorite stocks among the S&P Small Cap 600, along with another for the Russell 2000.

    Watch for a “head fake”

    Much of the small-cap buying in December might have resulted from covering of short positions by hedge-fund managers. This idea is backed by the timing of trading activity immediately following the Federal Open Market Committee’s announcement on Dec. 13 that it wouldn’t change its interest-rate policy, according to MacroTourist blogger Kevin Muir. The Fed’s economic projections released the same day also indicate three cuts to the federal-funds rate in 2024.

    Heading into the end of the year, a fund manager who had shorted small-caps, and then was surprised by the Fed’s interest-rate projections, might have scrambled to buy stocks it had shorted to close-out the positions and hopefully lock in gains, or limit losses.

    That buying activity and resulting pop in small-cap prices could set up a typical “head fake” for investors as the new year begins, according to Muir.

    The long-term case for quality

    Looking at data for companies’ most recently reported fiscal quarters, 58% of the Russell 2000 reported positive earnings per share, according to data provided by FactSet. In other words, hundreds of these companies were losing money. These might include promising companies facing “binary events,” such as make-or-break drug trials in the biotechnology industry.

    In comparison, 78% of companies among the S&P Small Cap 600 were profitable, and 93% of the S&P 500 were in the black.

    Here are long-term performance figures for exchange-traded funds that track all three indexes:

    ETF

    Ticker

    2023

    3 years

    5 years

    10 years

    15 years

    20 years

    iShares Russell 2000 ETF

    IWM 17%

    7%

    61%

    99%

    428%

    365%

    iShares Core S&P Small Cap ETF

    IJR 16%

    25%

    69%

    129%

    540%

    515%

    SPDR S&P 500 ETF Trust

    SPY 26%

    34%

    108%

    210%

    629%

    527%

    Source: FactSet

    An approach tracking the S&P Small Cap 600 has outperformed the Russell 2000 for all periods, with margins widening as you go further back.

    Brett Arends: You own the wrong small-cap fund. How to get into a better one.

    Looking ahead for quality… or not

    For the first screen, we began with the S&P Small Cap 600 and narrowed the list to 385 companies covered by at least five analysts polled by FactSet. Then we cut the list to 92 companies with “buy” or equivalent ratings among at least 75% of the covering analysts.

    Here are the 20 remaining stocks among the S&P Small Cap 600 with the highest 12-month upside potential indicated by analysts’ consensus price targets:

    Company

    Ticker

    Share “buy” ratings

    Dec. 29 price

    Consensus price target

    Implied 12-month upside potential

    Vir Biotechnology Inc.

    VIR,
    +4.47%
    88%

    $10.06

    $32.00

    218%

    Arcus Biosciences Inc.

    RCUS,
    +3.04%
    82%

    $19.10

    $41.00

    115%

    Xencor Inc.

    XNCR,
    +6.03%
    92%

    $21.23

    $39.83

    88%

    Dynavax Technologies Corp.

    DVAX,
    +2.86%
    100%

    $13.98

    $24.80

    77%

    ModivCare Inc.

    MODV,
    +0.95%
    100%

    $43.99

    $75.50

    72%

    Xperi Inc

    XPER,
    +1.81%
    80%

    $11.02

    $18.20

    65%

    Thryv Holdings Inc.

    THRY,
    100%

    $20.35

    $32.75

    61%

    Ligand Pharmaceuticals Inc.

    LGND,
    +1.25%
    100%

    $71.42

    $114.80

    61%

    Green Plains Inc.

    GPRE,
    -1.67%
    80%

    $25.22

    $40.30

    60%

    Patterson-UTI Energy Inc.

    PTEN,
    +0.28%
    75%

    $10.80

    $17.00

    57%

    Ironwood Pharmaceuticals Inc. Class A

    IRWD,
    +8.48%
    83%

    $11.44

    $17.83

    56%

    Catalyst Pharmaceuticals Inc.

    CPRX,
    +1.78%
    100%

    $16.81

    $26.20

    56%

    Payoneer Global Inc.

    PAYO,
    -3.45%
    100%

    $5.21

    $8.00

    54%

    Helix Energy Solutions Group Inc.

    HLX,
    -2.63%
    83%

    $10.28

    $15.00

    46%

    Arlo Technologies Inc.

    ARLO,
    -3.05%
    100%

    $9.52

    $13.80

    45%

    Pacira Biosciences Inc.

    PCRX,
    -5.16%
    100%

    $33.74

    $48.40

    43%

    Privia Health Group Inc.

    PRVA,
    +2.95%
    100%

    $23.03

    $32.53

    41%

    Semtech Corp.

    SMTC,
    -1.23%
    92%

    $21.91

    $30.90

    41%

    Talos Energy Inc.

    TALO,
    +1.19%
    78%

    $14.23

    $20.00

    41%

    Digi International Inc.

    DGII,
    -1.21%
    100%

    $26.00

    $36.14

    39%

    Source: FactSet

    Any stock screen should only be considered a starting point. You should do your own research to form your own opinion before making any investment. one way to begin is by clicking on the tickers for more about each company.

    Click here for Tomi Kilgore’s detailed guide to the wealth of information available for free on the MarketWatch quote page.

    Moving on to the Russell 2000, when we narrowed this group to stocks covered by at least five analysts polled by FactSet, we were left with 936 companies. Among these, 355 have “buy” or equivalent ratings among at least 75% of the covering analysts.

    Among those 355 stocks in the Russell 2000, these 20 have the highest implied upside over the next year, based on consensus price targets:

    Company

    Ticker

    Share “buy” ratings

    Dec. 29 price

    Consensus price target

    Implied 12-month upside potential

    Karyopharm Therapeutics Inc.

    KPTI,
    +4.18%
    75%

    $0.87

    $6.00

    594%

    Rallybio Corp.

    RLYB,
    +0.42%
    100%

    $2.39

    $16.50

    590%

    Vor Biopharma Inc.

    VOR,
    -0.89%
    100%

    $2.25

    $15.44

    586%

    Tenaya Therapeutics Inc.

    TNYA,
    -0.62%
    100%

    $3.24

    $19.14

    491%

    Compass Therapeutics Inc.

    CMPX,
    -5.13%
    86%

    $1.56

    $9.17

    488%

    Vigil Neuroscience Inc.

    VIGL,
    +2.66%
    88%

    $3.38

    $18.75

    455%

    Trevi Therapeutics Inc.

    TRVI,
    -2.99%
    100%

    $1.34

    $7.33

    447%

    Inozyme Pharma Inc.

    INZY,
    +1.64%
    100%

    $4.26

    $21.00

    393%

    Gritstone bio Inc.

    GRTS,
    +6.86%
    100%

    $2.04

    $10.00

    390%

    Actinium Pharmaceuticals Inc.

    ATNM,
    +4.72%
    83%

    $5.08

    $23.36

    360%

    Lineage Cell Therapeutics Inc.

    LCTX,
    86%

    $1.09

    $4.83

    343%

    Century Therapeutics Inc.

    IPSC,
    +9.64%
    86%

    $3.32

    $14.67

    342%

    Acrivon Therapeutics Inc.

    ACRV,
    +1.83%
    100%

    $4.92

    $21.13

    329%

    Avidity Biosciences Inc.

    RNA,
    +1.22%
    100%

    $9.05

    $37.50

    314%

    Longboard Pharmaceuticals Inc.

    LBPH,
    +316.25%
    100%

    $6.03

    $24.17

    301%

    Omega Therapeutics Inc.

    OMGA,
    -1.33%
    100%

    $3.01

    $12.00

    299%

    Allogene Therapeutics Inc.

    ALLO,
    +12.77%
    82%

    $3.21

    $12.79

    298%

    X4 Pharmaceuticals Inc.

    XFOR,
    +5.21%
    86%

    $0.84

    $3.26

    289%

    Caribou Biosciences Inc.

    CRBU,
    -2.79%
    89%

    $5.73

    $22.25

    288%

    Stoke Therapeutics Inc.

    STOK,
    +11.41%
    78%

    $5.26

    $19.33

    268%

    Source: FactSet

    That’s right — this Russell 2000 list is all biotech. And in case you are wondering if any companies are on both lists, the answer is no.

    Don’t miss: 11 dividend stocks with high yields expected to be well supported in 2024 per strict criteria

    Source link

  • Chaotic 'triple witching' set for Friday, as $5.3 trillion in options expire

    Chaotic 'triple witching' set for Friday, as $5.3 trillion in options expire

    Options contracts tied to more than $5 trillion worth of stocks, exchange-traded funds and indexes are set to expire on Friday as the latest “triple witching” expiration event collides with the rebalancing of the S&P 500 and Nasdaq-100.

    The result could be a high-octane, and potentially extremely volatile, session where tens of billions of contracts and shares could change hands, market strategists said.

    According to figures from Rocky Fishman, founder of Asym500, options with a notional value of $5.3 trillion are set to expire, with the biggest slug expiring ahead of the open.

    ASYM50

    On one side, many traders will be cashing in bullish bets that are deep in the money, while some roll their positions, forcing market-makers to continue to hedge their exposure.

    At the same time, managers of index-tracking funds will need to finish adjusting their holdings before the announced index changes take effect.

    Already, trading volume has been trending higher all week. In the U.S. market, 17 billion shares changed hands on Thursday, according to Steve Sosnick, chief market strategist at Interactive Brokers, during a phone interview with MarketWatch. That is up from 10.6 billion on Tuesday.

    “I expect to see enormous volumes tomorrow in a lot of popular names,” Sosnick said.

    “Not only will this one be the largest option expiration of the year (as is typical for December), but it is currently set up to become the largest SPX option expiration in more than a decade,” Fishman said in a report shared with MarketWatch.

    Brent Kochuba, founder of Spotgamma, an options-market analytics provider, went even further during a phone interview with MarketWatch: “This might be the biggest options expiration ever.”

    ASYM50

    As markets have rallied, traders have been scooping up bullish options contracts at a record pace, according to data from Cboe Global Markets, the biggest operator of options exchanges in the U.S.

    For S&P 500-linked options, typically the most popular product, 4.8 million contracts changed hands on Thursday, according to Cboe, a new record, surpassing the previous record from Nov. 14.

    Also, total call-trading volume for all U.S. equity options exceeded 30 million contracts on Wednesday, according to Goldman Sachs Group, making it one of the busiest days for trading in bullish contracts this year.

    Aggressive call-buying over the past month has helped push the S&P 500 to just shy of its record closing high, options-market experts said. The S&P 500
    SPX
    gained 8.9% in November, its best month of 2023, and the 18th best-performing month of the past 73 years. And it has continued to climb in December, having risen 3.3% through Thursday’s close, according to FactSet data.

    Earlier this week, options strategists warned that markets might run into trouble at 4,600 on the S&P 500. They warned that a “call wall” of open-interest in bullish contracts around that level could force market makers to put the breaks on the rally.

    Instead, bullish traders blew through the call wall, pushing it higher to 4,700, said Kochuba.

    The S&P 500 closed at 4,719.55 on Thursday, its highest close since Jan. 12, 2022, according to FactSet data. The index is now sitting within 1.75 percentage points of its record closing high of 4,796.56 on Jan. 3, 2022.

    Traders’ bullishness recently helped push the Cboe Volatility Index
    VIX,
    otherwise known as Wall Street’s “fear gauge,” to multiyear lows, according to FactSet data.

    To be sure, it isn’t just S&P 500 options and contracts tied to popular stocks like Tesla Inc.
    TSLA,
    +4.91%

    seeing explosive volume: Calls tied to the iShares Russell 2000 ETF
    IWM,
    which tracks the small-cap Russell 2000, hit 1.35 million contracts, the third-highest ever, according to Goldman. Activity in options contracts linked to small-cap stock indexes has surged since late October.

    Heavy call buying has pushed the put-call skew for S&P 500 options to its lowest level in a year, according to data from Goldman Sachs Group.

    This shows that investors have been scrambling to buy bullish contracts, while largely shunning bearish ones, as stocks marched higher. Goldman analysts described Friday as “the last major liquidity event of the year” in a note to clients obtained by MarketWatch.

    GOLDMAN SACHS

    “Triple Witching” days happen once a quarter. They are thusly named because options tied to single stocks, ETFs and indexes will expire, alongside index-tracking futures contracts. Options-market experts say they are typically associated with more intraday swings and higher trading volume.

    Making things even more interesting is the fact that the quarterly rebalancing of the S&P 500 and Nasdaq-100 is due to take effect after markets close on Friday.

    Normally routine, this quarter’s rebalancing is drawing outsize attention following an extremely rare ad hoc rebalancing over the summer to rein in the influence of megacap stocks in the Nasdaq-100.

    Earlier this month, Standard & Poor’s announced its rebalancing plans, which included reducing the weighting of two Magnificent Seven stocks, Apple Inc.
    AAPL,
    +0.08%

    and Alphabet Inc.
    GOOG,
    -0.57%

    GOOGL,
    -0.48%
    .
    At the same time, Amazon.com Inc.
    AMZN,
    -0.95%
    ,
    which is also part of the Mag 7, will see its weighting increased. Meanwhile, three companies will join the index, including Uber Inc.
    UBER,
    +0.86%
    ,
    while shares of three other companies depart.

    Kochuba believes Friday’s expiration could remove the last barrier holding stocks back from rocketing to record highs before the end of the year.

    “After OpEx, markets will be able to move more freely,” Kochuba said.

    Garrett DeSimone of OptionMetrics cautioned that investors shouldn’t place too much weight on options-market activity and other technical factors.

    “At the end of the day, macro trumps everything,” he said during an interview with MarketWatch.

    Source link